Brian O Mahony/X
Jul 21, 2025, 13:10
What’s Slowing Down Gene Therapy Uptake in Hemophilia? Brian O’Mahony Explains the Real-World Barriers
Brian O’Mahony, CEO of Irish Haemophilia Society,former President of WFH and EHC, highlights several key challenges that are currently limiting the widespread adoption of gene therapy in hemophilia in his recently shared post on X:
“Uncertainty about outcomes and side effects,
Complex reimbursement systems,
Availability of other excellent therapies,
Lack of center preparedness and resources.”
Despite the promise of a functional cure, real-world barriers continue to delay broader implementation.

Want to understand the future of gene therapy and how to overcome systemic obstacles?
Find the latest updates and expert commentary — only on Hemostasis Today, your trusted source for frontline academic insights in hematology and hemostasis.
-
Nov 18, 2026, 13:34Vincenzo De Angelis: Strengthening Plasma Management and Quality Control in Eastern Europe
-
Nov 18, 2026, 13:34Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
-
Nov 18, 2026, 13:34Nicolas Gendron: Towards Sustainable Anticoagulation
-
Nov 18, 2026, 13:33Breaking the Silence on Women and Girls with Bleeding Disorders – EHC
-
Nov 18, 2026, 13:32Maria Elisa Mancuso: Next-Generation Protein Therapies in Hemophilia
-
Nov 18, 2026, 13:25Maia Meier: Advocating for Women and Girls with Bleeding Disorders
-
Nov 18, 2026, 13:19Sjoerd Fabian Koopman: Exploring Tissue Distribution of Extended Half-Life Factor IX Concentrates
-
Nov 18, 2026, 13:16Ifeanyichukwu Ifechidere: Choosing Between Clot-Based and Chromogenic Coagulation Assays
-
Nov 18, 2026, 13:06Saurabh Mehta: Daily Iron Supplementation in Children and Adolescents